Although the FDA is the US regulator, its decisions on breast implants are widely referenced internationally because of the size of its evidence base and the global nature of implant manufacturers.
Notable FDA actions
- Requesting the withdrawal of certain macro-textured implants linked to BIA-ALCL.
- Introducing stronger labelling, including boxed warnings and patient decision checklists.
- Recommending consideration of screening for silent silicone rupture.
- Issuing communications on rarer conditions such as squamous cell carcinoma (BIA-SCC).
What it means for UK patients
FDA actions often inform or parallel UK guidance. Your care in the UK is governed by the MHRA, but FDA updates are a useful early signal of emerging issues.